Bailard, Inc. Kura Oncology, Inc. Transaction History

Bailard, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$12.22 - $19.57 $127,503 - $204,193	-10,434 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$15.42 - $21.72 $160,892 - $226,626	10,434 New	10,434 $195,000
Q2 2021 Aug 13, 2021	SELL	$20.85 - $29.88 $1.71 Million - $2.45 Million	-81,934 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$24.75 - $39.14 $1.04 Million - $1.64 Million	42,000 Added 105.17%	81,934 $2.32 Million
Q4 2020 Feb 03, 2021	BUY	$29.0 - $41.62 $89,900 - $129,021	3,100 Added 8.42%	39,934 $1.3 Million
Q3 2020 Nov 10, 2020	SELL	$16.3 - $30.64 $159,740 - $300,272	-9,800 Reduced 21.01%	36,834 $1.13 Million
Q2 2020 Aug 12, 2020	SELL	$7.95 - $18.81 $14,310 - $33,858	-1,800 Reduced 3.72%	46,634 $760,000
Q1 2020 Apr 16, 2020	BUY	$6.45 - $14.04 $38,700 - $84,240	6,000 Added 14.14%	48,434 $482,000
Q4 2019 Jan 31, 2020	BUY	$12.97 - $15.94 $69,181 - $85,023	5,334 Added 14.38%	42,434 $583,000
Q3 2019 Oct 18, 2019	SELL	$14.75 - $20.87 $20,650 - $29,218	-1,400 Reduced 3.64%	37,100 $563,000
Q1 2019 Apr 24, 2019	BUY	$13.73 - $16.87 $116,705 - $143,395	8,500 Added 28.33%	38,500 $639,000
Q1 2018 May 07, 2018	SELL	$14.5 - $23.4 $55,172 - $89,037	-3,805 Reduced 11.26%	30,000 $563,000
Q4 2017 Feb 08, 2018	BUY	$13.5 - $16.65 $456,367 - $562,853	33,805	33,805 $0

188

81.9M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $534M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.